Persistent Peripheral Inflammation Attenuates Morphine-induced Periaqueductal Gray Glial Cell Activation and Analgesic Tolerance in the Male Rat by Eidson, Lori N. & Murphy, Anne Z., PhD
Georgia State University
ScholarWorks @ Georgia State University
Neuroscience Institute Faculty Publications Neuroscience Institute
4-2013
Persistent Peripheral Inflammation Attenuates
Morphine-induced Periaqueductal Gray Glial Cell
Activation and Analgesic Tolerance in the Male Rat
Lori N. Eidson
Anne Z. Murphy PhD
Georgia State University, amurphy@gsu.edu
Follow this and additional works at: https://scholarworks.gsu.edu/neurosci_facpub
Part of the Neuroscience and Neurobiology Commons
This Article is brought to you for free and open access by the Neuroscience Institute at ScholarWorks @ Georgia State University. It has been accepted
for inclusion in Neuroscience Institute Faculty Publications by an authorized administrator of ScholarWorks @ Georgia State University. For more
information, please contact scholarworks@gsu.edu.
Recommended Citation
Eidson, L. N., Murphy, A. Z. Persistent Peripheral Inflammation Attenuates Morphine-Induced Periaqueductal Gray Glial Cell




Persistent	  Peripheral	  Inflammation	  Attenuates	  Morphine-­‐induced	  




Lori	  N.	  Eidson	  and	  Anne	  Z.	  Murphy	  










Anne	  Z.	  Murphy,	  Ph.D.	  
Neuroscience	  Institute	  
Georgia	  State	  University	  
100	  Piedmont	  Ave	  
Atlanta	  GA	  30303	  
Email:	  	  amurphy@gsu.edu	  
Phone:	  	  404/413.5332	  
Fax:	   404/413.5301	  
	  
	  
Running	  Title:	  morphine	  induced	  tolerance	  and	  glia	  activation	  in	  PAG	  
	  








Morphine	   is	   among	   the	   most	   prevalent	   analgesics	   prescribed	   for	   chronic	   pain.	   However,	  
prolonged	   morphine	   treatment	   results	   in	   the	   development	   of	   analgesic	   tolerance.	   An	  
abundance	   of	   evidence	   has	   accumulated	   indicating	   that	   CNS	   glial	   cell	   activity	   facilitates	   pain	  
transmission	  and	  opposes	  morphine	  analgesia.	  While	  the	  midbrain	  ventrolateral	  periaqueductal	  
gray	  (vlPAG)	  is	  an	  important	  neural	  substrate	  mediating	  pain	  modulation	  and	  the	  development	  
of	  morphine	  tolerance,	  no	  studies	  have	  directly	  assessed	  the	  role	  of	  PAG-­‐glia.	  	  Here	  we	  test	  the	  
hypothesis	   that	   morphine-­‐induced	   increases	   in	   vlPAG	   glial	   cell	   activity	   contribute	   to	   the	  
development	  of	  morphine	  tolerance.	  As	  morphine	  is	  primarily	  consumed	  for	  the	  alleviation	  of	  
severe	  pain,	  the	  influence	  of	  persistent	  inflammatory	  pain	  was	  also	  assessed.	  Administration	  of	  
morphine,	  in	  the	  absence	  of	  persistent	  inflammatory	  pain,	  resulted	  in	  the	  rapid	  development	  of	  
morphine	  tolerance	  and	  was	  accompanied	  by	  a	  significant	  increase	  in	  vlPAG	  glial	  activation.	  	  In	  
contrast,	   persistent	   inflammatory	   hyperalgesia,	   induced	   by	   intraplantar	   administration	   of	  
Complete	   Freund’s	   Adjuvant	   (CFA),	   significantly	   attenuated	   the	   development	   of	   morphine	  
tolerance.	  No	   significant	   differences	  were	   noted	   in	   vlPAG	   glial	   cell	   activation	   for	   CFA-­‐treated	  
animals	   versus	   controls.	   These	   results	   indicate	   that	   vlPAG	  glia	   are	  modulated	  by	   a	  persistent	  
pain	  state,	  and	  implicate	  vlPAG	  glial	  cells	  as	  possible	  regulators	  of	  morphine	  tolerance.	  
Perspective	  The	  development	  of	  morphine	  tolerance	  represents	  a	  significant	  impediment	  to	  
its	  use	  in	  the	  management	  of	  chronic	  pain.	  We	  report	  that	  morphine	  tolerance	  is	  accompanied	  
by	   increased	  glial	   cell	   activation	  within	   the	  vlPAG,	  and	   that	   the	  presence	  of	  a	  persistent	  pain	  




	   Chronic	  pain,	  defined	  as	  pain	  lasting	  more	  than	  3-­‐6	  months,	  will	  affect	  more	  than	  one	  in	  
three	   Americans	   at	   some	   point	   in	   their	   life64,	   66.	   Although	   morphine	   is	   one	   of	   the	   most	  
commonly	  prescribed	  analgesics76,	  secondary	  side	  effects	   (e.g.,	   tolerance)	   limit	   its	  efficacy	  for	  
long-­‐term	  chronic	  pain	  treatment8,	  28,	  48,	  49.	  In	  the	  absence	  of	  pain,	  morphine	  tolerance,	  defined	  
as	   the	   requirement	   for	   steadily	   larger	   doses	   of	   opioids	   to	   achieve	   the	   same	   analgesic	   effect,	  
develops	   quite	   rapidly19,	  48,	  54.	   In	   contrast,	   clinical	   studies	   have	   consistently	   reported	   that	   the	  
latency	   to	   develop	  morphine	   tolerance	   is	   increased	   in	   chronic	   pain	   sufferers,	   although	   dose	  
escalation	   is	   eventually	   required	   for	   the	  maintenance	   of	   analgesic	   efficacy77.	   Dose	   escalation	  
leads	  to	   increased	  risk	  of	  developing	  additional	  negative	  side	  effects,	   including	  anti-­‐analgesia,	  
addiction,	  withdrawal,	   and	   respiratory	  depression76,	   and	   is	  not	  always	   sufficient	   to	  overcome	  
tolerance	  and	  reinstate	  analgesic	  efficacy77.	  As	  over	  90%	  of	  chronic	  pain	  sufferers	  are	  treated	  
with	   opioids76,	   including	   morphine,	   elucidation	   of	   the	   mechanisms	   by	   which	   morphine	  
tolerance	  develops	  warrants	  investigation.	  
	   The	  midbrain	  ventrolateral	  periaqueductal	  gray	   (vlPAG)	  and	   its	  descending	  projections	  
to	   the	   rostral	   ventromedial	   medulla	   (RVM)	   and	   spinal	   cord,	   comprises	   an	   important	   neural	  
circuit	   for	   both	   endogenous	   and	   exogenous	   opioid-­‐mediated	   analgesia4-­‐7,	   24.	   In	   rats,	   chronic	  
subcutaneous	  injections	  of	  morphine	  result	   in	  tolerance	  to	  subsequent	  doses	  of	  morphine,	  an	  
effect	   that	   is	   eliminated	   by	   intra-­‐vlPAG	   injections	   of	   the	   opioid	   receptor	   antagonist	  
naltrexone42.	  In	  addition,	  chronic	  intra-­‐vlPAG	  injections	  of	  morphine	  induce	  tolerance,	  and	  this	  
effect	  remains	  when	  the	  RVM,	  the	  primary	  downstream	  target	  of	  the	  PAG,	  is	  inhibited	  with	  the	  
GABA	  agonist	  muscimol42.	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   An	   abundance	   of	   evidence	   has	   accumulated	   indicating	   that	   systemic	   morphine	  
administration	  activates	  glial	  cells,	  including	  microglia	  and	  astrocytes31,	  51,	  52,	  60,	  70,	  75,	  84.	  Song	  and	  
Zhou	   (2001)	   reported	   that	   chronic	   morphine	   administration	   results	   in	   the	   activation	   of	  
astrocytes	  within	  the	  cingulate	  cortex,	  hippocampus	  and	  spinal	  cord,	  and	  that	  blockade	  of	  glial	  
activation	   within	   the	   spinal	   cord	   attenuates	   the	   development	   of	   morphine	   tolerance.	   Since	  
then,	  a	  myriad	  of	  studies	  have	  been	  published	  implicating	  glia	  activation	  in	  the	  development	  of	  
morphine	   tolerance84,	   85	   and	   pain	   facilitation11,	   61,	   82.	   	  While	   it	   is	   clear	   that	   the	   activation	   of	  
microglia	  and	  astrocytes	  contribute	  to	  the	  development	  of	  morphine	  tolerance,	  no	  studies	  have	  
examined	  the	  role	  of	  activated	  glia	  within	  the	  PAG,	  a	  primary	  site	  of	  morphine	  action.	  Similarly,	  
the	  influence	  of	  a	  persistent	  inflammatory	  pain	  state	  on	  PAG	  glial	  cell	  activation	  has	  not	  been	  
assessed.	   The	  present	   study	   tested	   the	  hypothesis	   that	  morphine-­‐induced	   increases	   in	   vlPAG	  
glial	   cell	   activity	   contribute	   to	   the	   development	   of	   morphine	   tolerance,	   and	   that	   persistent	  
inflammatory	  pain	  alters	  this	  activation,	  resulting	  in	  the	  attenuation	  of	  morphine	  tolerance.	  	  
Materials	  and	  Methods	  
Subjects	  
Weight-­‐matched	   (250-­‐350g)	  male	   Sprague	  Dawley	   rats	   (Charles	  River,	  Wilmington,	  MA)	  were	  
pair-­‐housed	  on	  a	  12:12	  hour	  light:	  dark	  cycle.	  Access	  to	  food	  and	  water	  was	  available	  ad	  libitum	  
throughout	  the	  experiments	  except	  during	  behavioral	  testing.	  All	  studies	  were	  approved	  by	  the	  
Institutional	   Animal	   Care	   and	   Use	   Committee	   (IACUC)	   at	   Georgia	   State	   University,	   and	  
performed	  in	  strict	  compliance	  with	  Ethical	  Issues	  of	  the	  International	  Association	  for	  the	  Study	  
of	   Pain	   (IASP)	   and	   National	   Institute	   of	   Health	   (NIH).	   All	   efforts	   were	   made	   to	   reduce	   the	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number	   of	   animals	   used	   in	   these	   experiments	   and	   to	  minimize	   any	   possible	   suffering	   by	   the	  
animal.	  
Persistent	  Inflammatory	  Hyperalgesia	  
In	   a	   subset	   of	   animals,	   persistent	   inflammatory	   hyperalgesia	   was	   induced	   by	   injection	   of	  
complete	  Freund’s	  adjuvant	  (CFA;	  Mycobacterium	  tuberculosis;	  Sigma;	  200	  µl),	  suspended	  in	  an	  
oil/saline	  (1:1)	  emulsion,	  into	  the	  plantar	  surface	  of	  the	  right	  hindpaw	  as	  previously	  described46,	  
48,	   81.	   As	   intraplantar	   saline	   administration	   results	   in	   a	   short-­‐term	   inflammatory	   response,	  
control	   animals	   were	   restrained	   in	   a	   similar	   manner	   but	   did	   not	   receive	   an	   intraplantar	  
injection.	  
Experiment	  1:	  Influence	  of	  Persistent	  Inflammatory	  Pain	  on	  Morphine	  Tolerance	  
Twenty-­‐four	  hours	  following	  intraplantar	  CFA	  injection	  or	  handling,	  animals	  were	  administered	  
morphine	   (5	  mg/kg,	   sc;	   NIDA)	   or	   saline	   (1	  ml/kg,	   sc)	   once	   a	   day	   for	   three	   consecutive	   days	  
(CFA+Morphine;	   CFA+Saline;	   Handled+Morphine;	   Handled+Saline).	   The	   5	   mg/kg	   dose	   was	  
chosen	  based	  on	  our	  previous	  studies	  demonstrating	  this	   to	  be	  the	  50%	  effective	  dose	   (ED50)	  
for	   systemic	   morphine	   in	   male	   rats47,	   53,	   81.	   Baseline	   nociceptive	   thresholds	   were	   measured	  
before	   morphine	   or	   saline	   injections,	   and	   15	   minutes	   following	   the	   first	   and	   last	   injection	  
(Injection	  1	  and	   Injection	  3,	   respectively).	  Tolerance	  was	  assessed	  on	  Day	  5	   (Day	  1	  being	  CFA	  
administration),	  by	  injecting	  cumulative	  doses	  of	  morphine	  every	  20	  min,	  resulting	  in	  doses	  of	  
3.2,	  5.6,	  8.0,	  10.0	  and	  18.0	  mg/kg	  as	  previously	  described48.	   	  Nociception	  was	  assessed	  using	  
the	   paw	   thermal	   stimulator29	   15	   min	   after	   each	   injection81.	   	   Briefly,	   for	   this	   test,	   the	   rat	   is	  
placed	  in	  a	  clear	  Plexiglas	  box	  resting	  on	  an	  elevated	  glass	  plate	  maintained	  at	  30oC.	  A	  radiant	  
beam	  of	  light	  is	  positioned	  under	  the	  hindpaw	  and	  the	  time	  for	  the	  rat	  to	  remove	  the	  paw	  from	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the	   thermal	   stimulus	   is	   electronically	   recorded	   as	   the	   paw	   withdrawal	   latency	   (PWL).	   The	  
intensity	  of	   the	  beam	  was	   set	   to	  produce	  basal	  withdrawal	   rates	  of	  7-­‐9	   seconds.	   	  A	  maximal	  
PWL	  of	  20.48	  seconds	  was	  used	  to	  prevent	  excess	  tissue	  damage	  due	  to	  repeated	  application	  of	  
the	  noxious	  thermal	  stimulus.	  Animals	  were	  acclimated	  to	  the	  testing	  apparatus	  (30	  minutes	  a	  
day	   for	   3	   consecutive	   days)	   at	   the	   start	   of	   the	   experiment.	   All	   behavioral	   testing	   took	   place	  
between	   12:00pm	   and	   5:00pm	   (lights	   on	   at	   7:00am).	   All	   testing	   was	   conducted	   blind	   with	  
respect	  to	  group	  assignment	  (i.e.,	  morphine	  or	  saline	  treatment).	  
Behavioral	  data	  analysis	  and	  presentation	  
Behavioral	   data	   are	   expressed	   in	   raw	   seconds.	   Paw	   withdrawal	   latency	   data	   were	   analyzed	  
using	   repeated	   measures	   ANOVA	   for	   significant	   main	   effect	   of	   pain	   (CFA	   or	   handled)	   and	  
treatment	   (morphine	   or	   saline)	   across	   dose.	   Pre-­‐planned	   t-­‐tests	   were	   used	   to	   determine	  
specific	  group	  and	  dose	  differences	  when	  a	  significant	  main	  effect	  was	  observed.	  All	  values	  are	  
reported	  as	  Mean	  +	  S.E.M.;	  p<	  0.05	  was	  considered	  statistically	  significant.	  	  
Experiment	  2:	  Anatomical	  Assessment	  of	  Morphine	  Tolerance	  
Twenty-­‐four	  hours	  following	  intraplantar	  CFA	  or	  handling,	  animals	  were	  administered	  morphine	  
(5	  mg/kg;	  sc)	  or	  saline	  (1	  ml/kg;	  sc)	  once	  a	  day	  for	  three	  consecutive	  days	  as	  described	  above	  
(CFA+Morphine,	  CFA+Saline,	  Handled+Morphine,	  Handled+Saline).	  One	  hour	  following	  the	  last	  
injection	  of	  morphine	  or	  saline,	  animals	  were	  given	  a	  lethal	  dose	  of	  Nembutal	  (160	  mg/kg;	  i.p.)	  
and	  transcardially	  perfused	  with	  250	  ml	  of	  0.9%	  sodium	  chloride	  containing	  2%	  sodium	  nitrite	  
as	  a	  vasodilator	  to	  remove	  blood	  from	  the	  brain.	  Immediately	  following	  blood	  removal,	  300	  ml	  
of	  4%	  paraformaldehyde	  in	  0.1M	  phosphate	  buffer	  containing	  2.5%	  acrolein	  (Polysciences	  Inc.;	  
Warrington,	   PA)	   was	   perfused	   through	   the	   brain	   as	   a	   fixative.	   A	   final	   rinse	   with	   250	   ml	   of	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sodium	  chloride/sodium	  nitrite	  solution	  was	  perfused	  through	  the	  brain	  to	  remove	  any	  residual	  
acrolein.	   Brains	  were	   removed	   and	   placed	   in	   a	   30%	   sucrose	   solution	   and	   stored	   at	   4°C	   until	  
sectioning.	  To	  examine	  the	  acute	  effects	  of	  morphine	  on	  vlPAG	  glia	  activation,	  a	  separate	  group	  
of	  animals	  received	  one	  sc	  injection	  of	  morphine	  (or	  saline)	  and	  were	  sacrificed	  1	  or	  24	  hours	  
later.	   A	   separate	   group	   of	   animals	   (CFA+Morphine,	   CFA+Saline,	   Handled+Morphine,	  
Handled+Saline)	  were	  decapitated	   immediately	   following	  treatment	   for	  western	  blot	  analysis.	  
Brains	  were	  removed,	  flash	  frozen	  in	  2-­‐methyl-­‐butane	  on	  dry	  ice,	  and	  stored	  at	  -­‐80°C.	  
Immunohistochemistry	  
Hallmarks	  of	  glial	  cell	  activity	  include	  increased	  cytokine	  release	  that	  correlates	  with	  increased	  
expression	  of	  the	  protein	  markers	  glial	  fibrillary	  acetic	  protein	  (GFAP;	  astrocytes),	  and	  CD-­‐11b	  
(OX-­‐42;	   microglia)60.	   Further,	   increased	   glial	   cell	   activity	   is	   evidenced	   by	   a	   profound	   shift	   in	  
morphology	   that	   can	  be	  easily	   visualized	  using	   immunohistochemistry	   for	  GFAP	  and	  OX-­‐4216.	  
Perfused	   brains	   were	   sectioned	   into	   25µm	   coronal	   sections	   with	   a	   Leica	   2000R	   freezing	  
microtome	  and	  stored	  free-­‐floating	  in	  cryoprotectant-­‐antifreeze	  solution44	  at	  -­‐20°C.	  A	  1:6	  series	  
through	   the	   rostrocaudal	   axis	   of	   each	   brain	   was	   processed	   for	   GFAP	   and	   OX-­‐42	  
immunoreactivity	   using	   standard	   immunohistochemical	   techniques56.	   Briefly,	   sections	   were	  
rinsed	   extensively	   in	   potassium	   phosphate-­‐buffered	   saline	   (KPBS)	   immediately	   followed	   by	   a	  
20-­‐minute	   incubation	   in	   1%	   sodium	   borohydride.	   The	   tissue	   was	   then	   incubated	   in	   primary	  
antibody	   solution	   (rabbit	   anti-­‐GFAP	   1:5,000	   or	   rabbit	   anti-­‐OX42	   1:1000;	   Abcam)	   in	   KPBS	  
containing	  1.0%	  Triton-­‐X	  for	  one	  hour	  at	  room	  temperature	  followed	  by	  48	  hours	  at	  4°C.	  After	  
rinsing	  with	  KPBS,	   the	   tissue	  was	   incubated	   for	  one	  hour	   in	   secondary	  antibody	   (biotinylated	  
IgG	   goat	   anti-­‐rabbit	   1:600),	   rinsed	  with	   KPBS,	   and	   then	   incubated	   for	   one	   hour	   in	   an	   avidin-­‐
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biotin	  peroxidase	  complex	  (1:10;	  ABC	  Elite	  Kit,	  Vector	  Labs).	  After	  rinsing	   in	  KPBS	  and	  sodium	  
acetate	  (0.175	  M;	  pH	  6.5),	  GFAP	  or	  OX-­‐42	  immunoreactivity	  was	  visualized	  as	  a	  black	  reaction	  
product	   using	   nickel	   sulfate	   intensified	   3,3’-­‐diaminobenzidine	   (DAB)	   solution	   (2	   mg/10ml)	  
containing	   0.08%	   hydrogen	   peroxide	   in	   sodium	   acetate	   buffer.	   After	   15	  minutes,	   tissue	   was	  
rinsed	   in	   sodium	  acetate	  buffer	   followed	  by	  KPBS.	   In	  a	   subset	  of	   sections,	  GFAP	   (Rabbit	  anti-­‐
GFAP	   1:3,000;	   Abcam)	   or	   OX-­‐42	   (Mouse	   anti-­‐CD11b	   1:3000;	   Serotec)	   was	   visualized	   using	   a	  
fluorescent	   secondary	   antibody	   (goat	   anti-­‐rabbit	   Dylight488	   1:50	   for	   GFAP	   and	   rabbit	   anti-­‐
mouse	   Cy3	   1:50	   for	   CD11b;	   Jackson	   Immunoresearch	   Laboratories).	   	   Following	   secondary	  
incubation,	   sections	  were	  rinsed	   in	  KPBS.	  DAB	  and	   fluorescent	  sections	  were	  mounted	  out	  of	  
KPBS	  onto	  gelatin-­‐subbed	  slides,	  air-­‐dried	  and	  dehydrated	  in	  a	  series	  of	  graded	  alcohols.	  Tissue-­‐
mounted	  slides	  were	  then	  cleared	   in	  Xylenes	  and	  glass	  cover-­‐slipped	  using	  Permount	  for	  DAB	  
reactions	  or	  Krystalon	  for	  fluorescence.	  	  
Western	  blotting	  
Flash	   frozen	   brains	   were	   sectioned	   at	   300µm	   on	   a	   cryostat	   (Leica,	   Buffalo	   Grove,	   IL)	   and	  
mounted	  onto	  slides.	  One-­‐millimeter	  bilateral	  micropunches	  were	  taken	  from	  6	   levels	   for	   the	  
vlPAG	   (Bregma	   -­‐8.52,	   -­‐8.28,	   -­‐7.92,	   -­‐7.68,	   -­‐7.20,	   and	   -­‐6.96)58	   and	   6	   levels	   of	   the	   superior	  
colliculus	   (Bregma	   -­‐7.68,	   -­‐7.20,	   -­‐6.96,	   -­‐6.60,	   -­‐6.24,	  and	   -­‐5.80)58,	   and	  homogenized	   in	  a	  10mM	  
HEPES	  buffer	  (pH	  7.2).	  Equal	  amounts	  of	  protein	  (2µg)	  along	  with	  a	  standard	  marker	  (Bio-­‐Rad,	  
Hercules,	  CA)	  were	  run	  at	  100V	  for	  2	  hours	  through	  10%	  Tris-­‐HCl	  polyacrylamide	  gels	  (Bio-­‐Rad,	  
Hercules,	   CA),	   and	   electro-­‐transferred	   at	   4°C	   on	   ice	   at	   250mA	   for	   2	   hours	   onto	   PVDF	  
membranes	  (0.2µm	  pore	  size;	  Bio-­‐Rad,	  Hercules,	  CA).	  Membranes	  were	  blocked	  with	  5%	  milk	  in	  
TBS-­‐Tween	   20	   (1%)	   at	   4°C	   overnight,	   and	   probed	   with	   rabbit	   anti-­‐GFAP	   primary	   antibody	  
 9 
(1:300,000;	  Abcam)	  in	  2%	  milk/TBS-­‐Tween	  20	  (1%)	  for	  3	  hours	  at	  room	  temperature	  followed	  
by	  a	  30	  minute	  incubation	  in	  HRP-­‐conjugated	  goat	  anti-­‐rabbit	  secondary	  (1:5000;	  Abcam)	  in	  2%	  
milk/TBS-­‐Tween	   20	   (1%).	   Rabbit	   anti-­‐β−actin	   primary	   (1:10,000;	   Novus	   Biologicals)	   was	  
included	  as	  a	  control	  for	  protein	  loading.	  Membranes	  were	  stripped	  and	  reprobed	  with	  mouse	  
anti-­‐rat	   CD11b	   (OX-­‐42,	   1:700;	   Serotec)	   followed	   by	  HRP-­‐conjugated	   goat	   anti-­‐mouse	   (OX-­‐42;	  
1:5000;	  Abcam)	  and	  HRP-­‐conjugated	  goat	  anti-­‐rabbit	  (β-­‐actin;	  1:5000;	  Abcam)	  secondaries.	  	  	  	  
Anatomical	  data	  analysis	  and	  presentation	  
Levels	   of	   GFAP	   and	   OX-­‐42	   immunoreactivity	   in	   the	   vlPAG	   were	   compared	   across	   treatment	  
groups	  using	  semi-­‐quantitative	  densitometry	  as	  previously	  described43,	  48.	  To	  determine	   if	   the	  
observed	   changes	   in	   glia	   activation	  were	   limited	   to	   the	   vlPAG,	   sections	   through	   the	   superior	  
colliculus	   (SC),	   a	   region	   containing	   a	   high	   density	   of	   µ	   opioid	   receptors	   (MOR)	   but	   not	  
implicated	   in	   opioid	   modulation	   of	   pain,	   were	   also	   analyzed.	   12-­‐bit	   grayscale	   images	   that	  
included	   the	   region	  of	   interest	   (ROI)	  were	  captured	  using	  a	  QImaging	  Retiga	  EXi	  CCD	  camera	  
(Surrey,	   BC,	   Canada)	   and	   iVision	   Image	   analysis	   software	   (Biovision	   Technologies,	   Exton,	   PA).	  
Grayscale	   values	   for	   each	   image	  were	   inverted	   so	   that	   higher	   values	  were	   representative	   of	  
increased	   staining	   levels.	   Images	   of	   three	   slices	   through	   each	   ROI	   for	   each	   animal	   were	  
analyzed	  and	  data	  sampled	  unilaterally.	  Data	  sampling	  occurred	  by	  using	  the	  drawing	  tools	   in	  
iVision	  to	  outline	  the	  ROI	  and	  using	  the	  “measure”	  function	  to	  determine	  an	  average	  grayscale	  
pixel	   value	   for	   the	   outlined	   area.	   ROI	   measures	   were	   corrected	   for	   nonspecific	   binding	   by	  
subtraction	  of	   background	  measure	   taken	   from	  gray	  matter	   adjacent	   to	   the	  ROI.	   	  Data	  were	  
analyzed	  across	  3	  representative	  levels	  through	  the	  rostral-­‐caudal	  axis	  of	  the	  vlPAG	  (Bregma	  -­‐
7.08,	  -­‐7.68,	  and	  -­‐8.30)58	  and	  superior	  colliculus	  (Bregma	  -­‐7.68,	  -­‐6.24,	  and	  -­‐5.80)	  58	  as	  previously	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described48.	   Densitometry	   values	   are	   presented	   as	   the	   mean	   +	   S.E.M.	   density	   of	  
immunoreactivity.	  Data	  were	  analyzed	  using	  an	  ANOVA	  to	  determine	  significant	  main	  effects	  of	  
treatment	   (morphine,	   saline)	   and	   pain	   (CFA,	   handled).	   Fisher’s	   post	   hoc	   tests	   were	   used	   to	  
determine	  specific	  group	  differences	  when	  a	  significant	  main	  effect	  was	  observed;	  p	  <	  0.05	  was	  
considered	  statistically	  significant.	  For	  Western	  blots,	  band	  intensities	  for	  tissue	  from	  the	  vlPAG	  
and	  superior	  colliculus	  were	  visualized	  at	  55kD	  (GFAP)	  and	  160kD	  (CD11b),	  and	  quantified	  using	  
ImageJ	  (NIH,	  USA)	  analysis	  software,	  as	  a	  relative	  intensity	  of	  GFAP	  or	  CD11b	  band	  divided	  by	  
the	  intensity	  of	  the	  β−actin	  band.	  Data	  are	  expressed	  as	  the	  mean	  ratio	  +	  S.E.M	  of	  protein	  of	  
interest/β−actin.	   Data	   were	   analyzed	   for	   significant	   main	   effects	   of	   treatment	   (morphine,	  
saline)	   and	   pain	   (CFA,	   handled)	   using	   an	   ANOVA,	   and	   Fisher’s	   HSD	   was	   used	   for	   post-­‐hoc	  
analysis;	  p	  <	  0.05	  was	  considered	  statistically	  significant.	  
Results	  
Experiment	  1:	  Persistent	  Peripheral	  Inflammation	  Attenuated	  Morphine	  Tolerance	  	  
To	   assess	   the	   initial	   analgesic	   potency	   of	   morphine,	   and	   the	   degree	   and	   time	   course	   for	  
development	   of	   morphine	   tolerance,	   paw	   withdrawal	   latencies	   (PWL)	   were	   determined	   for	  
both	  the	  injured	  (ipsilateral;	  right)	  and	  uninjured	  (contralateral;	  left)	  hindpaws	  at	  baseline,	  and	  
after	   Day	   1	   and	   Day	   3	   of	   morphine	   or	   saline.	   Contralateral	   (uninjured)	   PWL	   did	   not	   differ	  
between	   CFA+Saline	   and	   Handled+Saline	   groups	   at	   any	   time	   point	   (Figure	   1A).	   By	   contrast,	  
intraplantar	  CFA	  significantly	  decreased	   ipsilateral	  PWL	  24,	  48,	  and	  96	  hours	  post	   injection	  as	  
compared	  with	  handled	  controls	   (CFA+Saline	  versus	  Handled+Saline;	  Figure	  1B)	   indicating	  the	  
development	   of	   persistent	   hyperalgesia.	   Administration	   of	   morphine	   on	   Day	   1	   and	   3	  
significantly	  increased	  both	  contralateral	  and	  ipsilateral	  PWLs	  as	  compared	  with	  saline	  controls	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(Figure	  1A	  and	  B,	  respectively).	  For	  the	  contralateral	  paw,	  administration	  of	  morphine	  (Day	  1)	  
produced	  comparable	  levels	  of	  analgesia	  in	  the	  CFA+Morphine	  and	  Handled+Morphine	  groups	  
(Figure	  1A).	  However,	  the	  degree	  of	  analgesia	  produced	  by	  morphine	  on	  Day	  3	  was	  significantly	  
attenuated	   in	   the	   Handled+Morphine	   vs.	   the	   CFA+Morphine	   animals,	   suggesting	   the	  
development	  of	  morphine	   tolerance	   (Figure	  1A).	   In	   the	   ipsilateral	  hindpaw,	  administration	  of	  
morphine	  on	  Day	  1	  produced	  anti-­‐hyperalgesia	  in	  CFA	  treated	  animals	  as	  indicated	  by	  a	  return	  
to	   normal	   baseline	   PWL	   (CFA+Morphine;	   Handled+Saline,	   Figure	   1B).	   In	   contrast	   to	   the	  
decreased	  analgesia	  observed	   in	  Handled+Morphine	  animals	  on	  Day	  3,	  morphine	  produced	  a	  
significant	   increase	   in	   ipsilateral	   PWL	   of	   injured	   animals	   on	   Day	   3	   as	   compared	   to	   Day	   1	  
(CFA+Morphine;	   Injection	   1	   and	   Injection	   3,	   Figure	   1B)	   indicating	   lack	   of	   tolerance	  
development.	  	  
Assessment	  of	  morphine	  tolerance	  	  
Morphine	  tolerance,	  assessed	  on	  Day	  5	  using	  a	  cumulative	  dosing	  paradigm,	  was	  only	  observed	  
in	  non-­‐CFA	  treated	  animals.	  As	  shown	  in	  Figure	  2,	  the	  antinociceptive	  potency	  of	  morphine	  was	  
significantly	  decreased	   in	  both	   the	   ipsilateral	   and	   contralateral	  hindpaw	  of	  uninjured	  animals	  
that	  received	  3	  consecutive	  days	  of	  morphine	  (Handled+Morphine)	  as	  compared	  with	  uninjured	  
animals	  that	  received	  saline	  (Handled+Saline;	  Figures	  2A	  and	  C).	  Indeed,	  animals	  that	  received	  3	  
days	   of	   saline	   reached	   100%	   maximum	   possible	   analgesia	   (MPE)	   at	   the	   8	   mg/kg	   dose.	   In	  
contrast,	   100%	  MPE	  was	  not	   noted	  until	   the	   18	  mg/kg	  dose	   in	   animals	   that	   received	  3	  prior	  
days	   of	  morphine.	  Neither	   the	   antinociceptive	   nor	   the	   antihyperalgesic	   potency	   of	  morphine	  
was	  different	   in	  CFA+Morphine	  treated	  animals	  as	  compared	  with	  CFA+Saline	  treated	  animals	  
(Figures	   2B	   and	  D)	   indicating	   lack	   of	   tolerance	   development.	   Indeed,	   no	   differences	   in	   PWLs	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produced	   by	   morphine	   were	   noted	   for	   all	   doses	   tested.	   Together	   these	   data	   indicate	   that	  
persistent	  inflammatory	  pain	  attenuates	  the	  development	  of	  tolerance	  to	  morphine.	  	  
As	   glia	   activation	   in	   the	   spinal	   cord	   has	   been	   implicated	   in	   the	   development	   of	   morphine	  
tolerance,	   the	  next	   series	  of	  experiments	  examined	   if	   glia	  were	   similarly	  activated	  within	   the	  
vlPAG,	  and	  if	  persistent	  inflammatory	  pain	  altered	  their	  activation.	  	  
Experiment	   2:	  Morphine	   Tolerance	   is	   Associated	  with	   Increased	   Glial	   Cell	   Activation	   in	   the	  
vlPAG	  
Increased	   activity	   of	   astrocytes,	   as	   evidenced	   by	   an	   increase	   in	   GFAP	   immunoreactivity,	  was	  
only	  observed	  in	  non-­‐CFA	  treated	  animals	  that	  received	  morphine	  (Handled	  +Morphine,	  Figure	  
3B).	  A	  representative	  example	  of	  vlPAG	  GFAP	  staining	  in	  animals	  administered	  CFA+Morphine	  
versus	  Handled+Morphine	  is	  shown	  in	  Figure	  3A.	  Western	  blots	  confirmed	  increased	  activity	  of	  
astrocytes,	   as	   evidenced	  by	   an	   increase	   in	   relative	  band	   intensity	   of	  GFAP/	  β-­‐actin,	  was	  only	  
observed	  in	  non-­‐injured	  animals	  that	  received	  morphine	  (Handled+Morphine,	  Figure	  3C).	  	  
Similar	   to	   what	   was	   noted	   for	   astrocytes,	   microglia	   activity,	   as	   evidenced	   by	   OX-­‐42	  
immunoreactivity,	  was	  significantly	  increased	  in	  animals	  that	  received	  morphine	  in	  the	  absence	  
of	  pain	   (Handled+Morphine,	   Figure	  4B).	  A	   representative	  example	  of	   vlPAG	  OX-­‐42	   staining	   in	  
animals	  administered	  CFA+Morphine	  versus	  Handled+Morphine	  is	  shown	  in	  Figure	  4A.	  A	  trend	  
towards	  increased	  activity	  of	  microglia,	  as	  evidenced	  by	  an	  increase	  in	  relative	  band	  intensity	  of	  
OX-­‐42/β-­‐actin,	   was	   only	   observed	   in	   animals	   that	   received	  morphine	   in	   the	   absence	   of	   pain	  
(Handled+Morphine,	   Figure	   4C);	   however,	   it	   did	   not	   reach	   statistical	   significance.	   Peripheral	  
inflammation	   induced	  by	   intraplantar	  CFA	  did	  not	   illicit	  significant	   increases	   in	  vlPAG	  glial	  cell	  
activity	  (Figures	  3	  and	  4).	  Importantly,	  one	  injection	  of	  morphine	  (5	  mg/kg)	  was	  not	  sufficient	  to	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alter	  vlPAG	  GFAP	  (Figure	  5A)	  or	  OX-­‐42	  levels	  (Figure	  5B)	  at	  24	  hours	  post-­‐morphine.	  Similarly,	  
no	   increase	   in	  GFAP	  or	  OX-­‐42	   levels	  were	  noted	  1	  hour	  post-­‐morphine	   	   (data	  not	  shown).	  No	  
significant	  group	  differences	  were	  noted	  in	  superior	  colliculus	  GFAP	  or	  OX-­‐42	  immunoreactivity	  
(F3,23=2.089,	   p=0.1295	   and	   F3,19=1.416,p=0.2690,	   respectively)	   or	   protein	   level	   (F3,28=0.232,	  
p=0.8730	   and	   F3,6=1.822,	   p=0.2435,	   respectively),	   indicating	   that	   changes	   in	   vlPAG	   glial	   cell	  
activity	  are	  region	  specific	  (data	  not	  shown).	  	  
Discussion	  	  
The	  present	  experiments	  tested	  the	  hypothesis	  that	  vlPAG	  glial	  cell	  activity	  contributes	  to	  the	  
development	  of	  morphine	  tolerance.	  Clinical	  studies	   indicate	  that	  chronic	  pain	  attenuates	  the	  
development	   of	   morphine	   tolerance37,	   77; however,	   animal	   studies	   have	   yielded	   variable	  
results35,	   65,	   78.	   Therefore,	   the	   impact	   of	   persistent	   inflammatory	   hyperalgesia	   on	   morphine	  
tolerance	   development	   and	   glial	   activation	   were	   also	   investigated.	   Here	   we	   report	   that	   (1)	  
short-­‐term	  daily	  administration	  of	  an	  ED50	  dose	  of	  morphine	  was	  sufficient	  to	  induce	  morphine	  
tolerance;	  (2)	  persistent	  inflammatory	  pain	  induced	  by	  intraplantar	  CFA	  significantly	  attenuated	  
morphine	  tolerance;	  and	  (3)	  increased	  vlPAG	  microglia	  and	  astrocyte	  activity	  was	  only	  observed	  
in	  those	  animals	  made	  tolerant	  to	  morphine.	  Together,	  these	  data	  suggest	  a	  potential	  role	  for	  
vlPAG	  microglia	   and	   astrocytes	   in	   the	   development	   of	  morphine	   tolerance,	   and	   suggest	   that	  
persistent	   inflammatory	   pain	   attenuates	  morphine	   tolerance	   by	   inhibiting	  morphine-­‐induced	  
vlPAG	  glial	  cell	  activation.	  	  	  
Increases	   in	   vlPAG	   microglia	   and	   astrocyte	   activity	   correlate	   with	   the	   development	   of	  
morphine	  tolerance	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Many	  mechanisms	  have	  been	  proposed	  to	  account	  for	  opioid	  tolerance,	   including	  decoupling,	  
internalization	   and/or	   down-­‐regulation	   of	   µ	   opioid	   receptors67,	   68,	   upregulation	   of	   NMDA	  
receptor	   function1-­‐3,	   down-­‐regulation	   of	   glutamate	   transporters9,	   59,	   and	   production	   of	   nitric	  
oxide	   (a	   known	   mediator	   of	   NMDAR	   function)84.	   These	   mechanisms	   were	   all	   thought	   to	  
implicate	  some	  form	  of	  ‘neuronal	  adaptation’84.	  However,	  it	  is	  becoming	  increasingly	  clear	  that	  
activated	   glia	   mediate	   many	   of	   these	   ‘neuronal	   adaptations’	   that	   contribute	   to	   morphine	  
tolerance84.	   Consistent	   with	   previous	   reports,	   here	   we	   find	   that	   tolerance	   to	   morphine	  
developed	  rapidly	  in	  the	  absence	  of	  pain41,	  42,	  48.	  Indeed,	  one	  ED50	  dose	  of	  morphine	  (5	  mg/kg)	  
injected	  subcutaneously	  for	  three	  days	  was	  sufficient	  to	  induce	  behaviorally	  defined	  tolerance.	  
Paralleling	  the	  development	  of	  tolerance,	  GFAP	  and	  OX-­‐42	  protein	  levels	  increased	  significantly	  
within	  the	  vlPAG,	  suggesting	  the	  activation	  of	  astrocytes	  and	  microglia,	  respectively.	  	  
A	  large	  body	  of	  evidence	  has	  accumulated	  implicating	  opioids	  as	  activators	  of	  spinal	  astrocytes	  
and	   microglia31,	   60,	   63,	   86.	   In	   both	   mice	   and	   rats,	   morphine	   increases	   spinal	   GFAP	   and	   OX-­‐42	  
protein	  levels,20,	  33	  	  as	  well	  as	  glially	  derived	  proinflammatory	  cytokines32,	  63.	  Inhibition	  of	  spinal	  
glia	   or	   cytokine	   release	   increases	   the	   analgesic	   efficacy	   of	   morphine32,	   63,	   and	   attenuates	  
morphine	  tolerance31,	  51,	  52,	  60,	  70.	  Our	  novel	  findings	  in	  the	  vlPAG	  parallel	  the	  data	  from	  studies	  
of	   spinal	   cord	   glia,	   and	   indicate	   that	   supraspinal	   glial	   cell	   activity	  may	   also	   contribute	   to	   the	  
development	  of	  morphine	  tolerance.	  	  
Under	  basal	  conditions	  glia	  survey	  the	  environment	  for	  pathogens,	  debris,	  and	  regulate	  ion	  and	  
neurotransmitter	  levels	  in	  the	  synapse	  to	  modulate	  neuronal	  excitability86.	  The	  activation	  of	  glia	  
results	   in	   the	   release	   of	   excitatory	   substances	   that	   oppose	   morphine	   analgesia	   (e.g.,	  
proinflammatory	  cytokines)86.	  Glial	   release	  of	  cytokines	   increases	  with	  chronicity	  of	  morphine	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administration84,	   making	   these	   excitatory	   substances	   key	   players	   in	   the	   development	   of	  
morphine	   tolerance.	  Glially-­‐derived	   cytokine	   release,	   particularly	   tumor	   necrosis	   factor	   alpha	  
(TNFα)	  and	  interleukin-­‐1	  beta	  (IL-­‐1β),	  results	  in	  increased	  density	  and	  conductance	  of	  neuronal	  
AMPA57,	  71	  and	  NMDA79	  receptors,	  decreased	  astrocytic	  glutamate	  transporter	  proteins	  (GLT-­‐1,	  
GLAST)86,	  and	  down-­‐regulation	  of	  neuronal	  GABA	  receptors71.	  These	  cytokine-­‐induced	  changes,	  
among	   others39,	   55,	   effectively	   increase	   neuronal	   excitability.	   Morphine	   binds	   to	   neuronal	   µ	  
opioid	   receptors	   (MOR)	   in	   the	  vlPAG	  that	  are	  primarily	   located	  on	  GABAergic	  neurons14,	  18,	  38;	  
MOR	  binding	  in	  the	  vlPAG	  disinhibits	  GABAergic	  PAG-­‐RVM	  projection	  neurons25,	  resulting	  in	  the	  
net	   excitation	   of	   the	   PAG-­‐RVM-­‐spinal	   cord	   descending	   pain	  modulatory	   circuit.	   Glial-­‐induced	  
increases	   in	   the	  excitability	  of	   vlPAG	  MOR-­‐containing	  neurons	  may	  act	   to	  alter	   the	   inhibitory	  
properties	   of	   morphine,	   thereby	   decreasing	   analgesic	   efficacy	   and	   contributing	   to	   the	  
development	  of	  morphine	  tolerance.	  
Persistent	   inflammatory	   pain	   prevented	   morphine-­‐induced	   increases	   in	   vlPAG	   glial	   cell	  
activity	  and	  attenuated	  the	  development	  of	  morphine	  tolerance	  
The	  results	  of	  the	  present	  study	  demonstrate	  that	  the	  presence	  of	  persistent	  pain	  alters	  both	  
the	  development	  of	  morphine	  tolerance	  and	  morphine-­‐induced	  vlPAG	  glial	  cell	  activation.	  The	  
finding	   that	   persistent	   peripheral	   inflammation	   attenuates	   morphine	   tolerance	   is	   consistent	  
with	   the	   clinical	   literature	   demonstrating	   that	   opioid	   tolerance	   is	   attenuated	   in	   chronic	   pain	  
sufferers17,	   23,	   26.	   Indeed,	   clinical	   studies	   have	   repeatedly	   shown	   that	   morphine	   tolerance	  
develops	  most	  robustly	  in	  those	  individuals	  consuming	  morphine	  in	  the	  absence	  of	  pain19,	  54.	  In	  
the	   present	   study,	   male	   rats	   given	   CFA	   24	   hours	   before	   the	   3-­‐day	  morphine	   administration	  
regimen	   showed	   significant	   increases	   in	   analgesia	   to	   all	   challenge	   doses	   of	   morphine,	   as	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compared	   with	   non-­‐injured	   animals.	   Several	   factors	   may	   contribute	   to	   the	   pain-­‐induced	  
attenuation	   in	   morphine	   tolerance.	   First,	   morphine,	   given	   in	   conjunction	   with	   peripheral	  
inflammation,	  failed	  to	  illicit	  the	  increases	  in	  vlPAG	  microglia	  and	  astrocyte	  activity	  observed	  in	  
non-­‐CFA	   treated	  animals	  given	  morphine.	   Indeed,	  peripheral	   inflammatory	  pain	  blocked	  both	  
morphine	  tolerance	  and	  morphine-­‐induced	  glial	  cell	  activation	  within	  the	  vlPAG.	  As	  glia	  are	  not	  
activated,	  no	  cytokine	   release	  would	  be	  expected,	  and,	   therefore,	  no	  net	  change	   in	  neuronal	  
excitability.	   Alternatively,	   cannabinoids,	  which	   are	   released	  within	   the	   PAG	  during	   peripheral	  
pain80,	  have	  been	  shown	  to	   influence	  both	  glial	  activity	  and	  morphine	  analgesia.	  Cannabinoid	  
receptor	   is	   robustly	   expressed	   within	   the	   vlPAG,	   with	   approximately	   32%	   of	   cannabinoid	  
receptor	  1	  (CB1)	  expressing	  neurons	  also	  expressing	  µ	  opioid	  receptor88.	  Functionally,	  intra-­‐PAG	  
administration	  of	  a	  CB1	  agonist	  enhances	  morphine	  analgesia87,	  and	  systemic	  administration	  of	  
cannabinoids,	   along	  with	  morphine,	   leads	   to	   the	   attenuation	   of	  morphine	   tolerance15,	   69,	   87	   .	  
Endocannabinoids	  also	  possess	  potent	  anti-­‐inflammatory	  properties22,	  which	  would	  likely	  block	  
the	  activation	  of	  glia.	  Indeed,	  systemic	  administration	  of	  the	  cannabinoid	  receptor	  agonist	  WIN	  
55,212-­‐2	   prevents	   microglia	   and	   astrocyte	   activation,	   and	   decreases	   the	   release	   of	   the	  
proinflammatory	   cytokines	   interleukin	   (IL)-­‐1β,	   IL-­‐6	   and	   tumor	   necrosis	   factor	   (TNF)-­‐α	   in	   the	  
spinal	  cord10.	  	  
In	  the	  present	  study,	  no	  glia	  activation	  was	  noted	  following	  administration	  of	  CFA	  alone.	  These	  
results	   are	   in	   contrast	   with	   previous	   reports	   that	   peripheral	   pain,	   including	   CFA13,	   50,	   62,	   72,	  
peripheral	   neuropathy16,	   21,	   27,	   62,	   73,	   74,	   83,	   	   formalin45,	   and	   spinal	   nerve	   ligation30	   induce	  
significant	  glia	  activation	  within	  the	  spinal	  cord.	  However,	  given	  the	  roles	  of	  the	  spinal	  cord	  and	  
PAG	  in	  pain	  facilitation	  and	  pain	  modulation,	  respectively,	  it	  is	  not	  entirely	  surprising	  that	  there	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would	   be	   differential	   pain-­‐induced	   regulation	   of	   glial	   activation	   in	   these	   two	   sites.	   Together,	  
these	   studies	   suggest	   that	   inflammation	   elicits	   differential	   glial	   responses	   in	   a	   CNS	   region-­‐
dependent	  manner,	  and	  prevents	  morphine-­‐induced	  increases	  in	  vlPAG	  glial	  cell	  activity.	  	  
How	  opioids	  activate	  glia	  
Opioid	   hyperalgesia	   is	   still	   observed	   in	   neuronal	   opioid	   receptor	   (mu,	   delta,	   and	   kappa)	  
knockout	  mice36,	  suggesting	  that	  the	  anti-­‐analgesic	  affects	  of	  morphine	  (e.g.,	  anti-­‐analgesia	  and	  
tolerance)	  are	  mediated	  by	  non-­‐neuronal	  opioid	  receptors.	   Indeed,	   it	  was	  recently	  discovered	  
that	  morphine	  analgesia	   is	  modulated	  not	  only	  by	  classical	  neuronal	  opioid	  receptors	  but	  also	  
by	  non-­‐classical	  glial	  receptor	  activity34.	  Opioids	  have	  been	  shown	  to	  bind	  to	  Toll-­‐like	  receptor	  4	  
(TLR4)34,	  an	  innate	  immune	  receptor	  located	  on	  microglia	  and	  astrocytes,	  and	  an	  abundance	  of	  
evidence	   has	   accumulated	   indicating	   that	   TLR4	   activity	   opposes	   morphine	   analgesia34,	   86.	  
Functionally,	   animals	   that	   receive	   TLR4	   antagonism,	   as	   well	   as	   TLR4	   knockout	   mice,	   exhibit	  
increased	   responsiveness	   to	   the	   analgesic	   properties	   of	   acute	   morphine	   administration86.	  
Similarly,	   systemic	   administration	   of	   TLR4	   antagonists	   attenuates	   morphine	   tolerance34.	   To	  
date,	   the	   specific	   role	   of	   TLR4	   in	  morphine	   tolerance	   development	   has	   not	   been	   elucidated.	  
However,	   given	   our	   findings	   that	   the	   development	   of	   morphine	   tolerance	   correlates	   with	  
increased	   vlPAG	  glial	   cell	   activation,	   and	   the	  evidence	   showing	   that	   TLR4	   is	   expressed	  on	   rat	  
PAG	  glia12,	  40,	  future	  studies	  investigating	  the	  potential	  role	  of	  vlPAG	  TLR4	  in	  the	  development	  
of	  morphine	  tolerance	  are	  warranted.	  	  
Conclusions	  
There	  is	  extensive	  literature	  supporting	  a	  critical	  role	  for	  glial	  cell	  activation	  in	  the	  development	  
of	  morphine	   tolerance.	  Our	   findings	   that	   increased	  vlPAG	  glial	   activity	   is	   concurrent	  with	   the	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development	   of	   morphine	   tolerance,	   and	   that	   pain	   inhibits	   both	   vlPAG	   glial	   reactivity	   and	  
morphine	   tolerance	   development	   suggests	   that	   vlPAG	   glia	   play	   a	   significant	   role	   in	   the	  
development	   of	   morphine	   tolerance.	   Taken	   together,	   our	   results	   may	   provide	   a	   direct	  
neurobiological	  mechanism	  whereby	  chronic	  inflammatory	  pain	  attenuates	  the	  development	  of	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FIGURE	  LEGENDS	  
Figure	  1.	  Contralateral	  (A)	  and	  ipsilateral	  (B)	  PWL	  (in	  seconds)	  following	  intraplantar	  CFA	  or	  
handling	  (Baseline),	  and	  after	  the	  first	  and	  third	  injection	  of	  morphine	  or	  saline	  in	  
CFA+Morphine	  (n=6),	  CFA+Saline	  (n=7),	  Handled+Morphine	  (n=6),	  and	  Handled+Saline	  (n=5)	  
treated	  male	  rats.	  The	  first	  and	  third	  injection	  of	  morphine	  caused	  an	  increase	  in	  contralateral	  
and	  ipsilateral	  PWL	  as	  compared	  with	  saline	  controls	  (p<	  0.05;	  A	  &	  B,	  respectively).	  
Contralateral	  PWL	  did	  not	  differ	  between	  CFA+Saline	  and	  Handled+Saline	  groups	  at	  any	  time	  
point	  (p>	  0.05;	  A).	  CFA	  treatment	  caused	  a	  significant	  decrease	  in	  ipsilateral	  PWL	  at	  all	  time	  
points	  as	  compared	  with	  handled	  controls	  (p<	  0.05;	  CFA+Saline;	  Handled+Saline;	  B).	  While	  
uninjured	  animals	  treated	  with	  morphine	  showed	  a	  decrease	  in	  analgesia	  to	  the	  third	  injection	  
as	  compared	  with	  the	  first	  (p<	  0.05;	  A),	  CFA	  treated	  animals	  showed	  an	  increase	  in	  
antihyperalgesia	  to	  the	  third	  injection	  (p<	  0.05;	  B).	  Asterisks	  indicate	  significant	  differences	  
between	  CFA+Morphine	  and	  Handled+Morphine	  groups.	  
	  
Figure	  2.	  PWL	  (in	  seconds)	  as	  a	  function	  of	  cumulative	  doses	  of	  morphine	  in	  handled	  (A	  &	  C),	  
and	  CFA	  treated	  (B	  &	  D)	  male	  rats.	  Both	  ipsilateral	  (A	  &	  B)	  and	  contralateral	  (C	  &	  D)	  PWL	  data	  
are	  presented.	  Animals	  received	  3	  consecutive	  days	  of	  morphine	  (5	  mg/kg;	  sc,	  open	  circles)	  or	  
saline	  (1	  ml/kg;	  sc,	  filled	  circles).	  CFA+Morphine	  treated	  animals	  (n=7)	  did	  not	  differ	  from	  
CFA+Saline	  treated	  animals	  (n=	  4)	  in	  response	  to	  cumulative	  morphine	  on	  day	  5	  (ipsilateral;	  
F1,9=1.128,p=0.3159	  &	  contralateral;	  F1,9=1.470,p=0.2563).	  Handled+Morphine	  treated	  animals	  
(n=	  9)	  showed	  a	  significant	  decrease	  in	  PWL	  in	  response	  to	  cumulative	  morphine	  on	  day	  5	  as	  
compared	  with	  Handled+Saline	  animals	  (n=5;	  ipsilateral;	  F1,12	  =21.702,p=0.0006	  &	  contralateral;	  
F1,12=20.373,p=0.0007).	  
	  
Figure	  3.	  	  Representative	  fluorescent	  photomicrographs	  of	  GFAP	  immunoreactivity	  in	  the	  vlPAG	  
of	  animals	  treated	  with	  CFA+Morphine	  (a)	  and	  Handled+Morphine	  (b)	  (A).	  Densitometry	  of	  
GFAP	  immunoreactivity	  in	  the	  vlPAG	  (B).	  	  Administration	  of	  morphine,	  in	  the	  absence	  of	  CFA	  
(Handled+Morphine;	  n=7),	  resulted	  in	  a	  significant	  increase	  in	  GFAP	  immunoreactivity	  within	  
the	  vlPAG	  (F3,22=10.022,	  p=0.0002).	  No	  differences	  in	  GFAP	  levels	  were	  noted	  for	  the	  
CFA+Morphine	  (n=11),	  CFA+Saline	  (n=4)	  or	  Handled+Saline	  control	  groups	  (n=4).	  Relative	  band	  
intensity	  of	  GFAP/β-­‐actin	  in	  the	  vlPAG	  (C).	  Administration	  of	  morphine,	  in	  the	  absence	  of	  CFA	  
(Handled+Morphine;	  n=5),	  resulted	  in	  a	  significant	  increase	  in	  relative	  band	  intensity	  of	  
GFAP/β-­‐actin	  in	  the	  vlPAG	  (F3,19=10.256,	  p=0.0003).	  No	  differences	  in	  GFAP	  levels	  were	  noted	  
for	  the	  CFA+Morphine	  (n=5),	  CFA+Saline	  (n=7)	  or	  Handled+Saline	  (n=6)	  control	  groups.	  
	  
Figure	  4.	  Representative	  fluorescent	  photomicrographs	  of	  OX-­‐42	  immunoreactivity	  in	  the	  vlPAG	  
of	  animals	  treated	  with	  CFA+Morphine	  (a)	  and	  Handled+Morphine	  (b)	  (A).	  Densitometry	  of	  OX-­‐
42	  immunoreactivity	  in	  the	  vlPAG	  (B).	  	  Administration	  of	  morphine,	  in	  the	  absence	  of	  CFA	  
(Handled+Morphine;	  n=8),	  significantly	  increased	  OX-­‐42	  immunoreactivity	  within	  the	  vlPAG	  
(F3,19=9.270,	  p=0.0005).	  No	  differences	  in	  OX-­‐42	  levels	  were	  noted	  for	  the	  CFA+Morphine	  (n=7),	  
CFA+Saline	  (n=4)	  or	  Handled+Saline	  (n=4)	  control	  groups.	  Relative	  band	  intensity	  of	  OX-­‐42/β-­‐
actin	  in	  the	  vlPAG	  (C).	  Administration	  of	  morphine,	  in	  the	  absence	  of	  CFA	  (Handled+Morphine;	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n=5),	  resulted	  in	  an	  increase	  in	  relative	  band	  intensity	  of	  OX-­‐42/β-­‐actin	  in	  the	  vlPAG	  
(F3,10=2.544,	  p=0.1151);	  however,	  it	  did	  not	  reach	  significance.	  	  
	  
Figure	  5.	  Densitometry	  of	  GFAP	  (A)	  and	  OX-­‐42	  (B)	  immunoreactivity	  in	  the	  vlPAG	  in	  
Handled+Morphine	  (n=3),	  CFA+Morphine	  (n=4),	  Handled+Saline	  (n=4),	  and	  CFA+Saline	  (n=5)	  
animals	  24	  hours	  following	  one	  morphine	  or	  saline	  injection.	  Neither	  CFA	  nor	  morphine	  (5	  
mg/kg,	  sc)	  increased	  vlPAG	  GFAP	  (F(3,12)=0.494;	  p=0.693)	  or	  OX-­‐42	  (F(3,12)=0.162;	  p=0.9198)	  
levels	  in	  the	  vlPAG	  as	  compared	  to	  handled	  and	  saline	  controls.	  
	  
	  
	  
	  
	  
	  
 
 
